Skip to main content

Security report for biogen.de

Biogen · Healthcare · Germany

Low risk. 2 critical or high findings in Email security and SSL/TLS.

Security score

78/100

Risk levelLow

0–100, higher is better. How it is calculated

Biogen Deutschland operates as a leading biotechnology company specializing in the research, development, and provision of innovative pharmaceutical therapies targeting complex and severe diseases, particularly in neurology and rare disorders. The website reflects a mature enterprise-level digital presence with comprehensive content tailored to patients, healthcare professionals, and partners. The company maintains a strong market position with a clear focus on innovation and patient care. Technically, the site leverages Adobe Experience Manager CMS, integrates modern analytics and consent management tools, and is hosted on AWS infrastructure, indicating a robust and scalable platform. Security posture is solid with HTTPS enforcement and cookie consent mechanisms, though there is room for improvement in explicit security policy disclosures and security headers. Overall, the site demonstrates high professionalism, compliance with GDPR, and trustworthy branding.

Scanned

NIS2 and GDPR posture

GDPR outside view
83/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching biogen.de

This scan found 19 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
72
Security headers
95
Email security
60
DNS health
60
Network security
100
GDPR outside view
83
Average
78

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Biogen's market positioning as a global biotechnology leader is supported by a diverse portfolio of therapies addressing neurological and immunological conditions. The business model centers on pharmaceutical innovation and patient-centric services, targeting healthcare providers and patients. The website's multilingual and regional domain structure indicates a broad international footprint. The absence of direct contact emails or phone numbers suggests a controlled communication channel via contact forms, aligning with corporate compliance standards. The company’s digital ecosystem includes social media engagement and comprehensive cookie management, reflecting a mature marketing and compliance strategy.

Security posture

The website demonstrates a good security baseline with HTTPS, HttpOnly cookies, and a robust cookie consent framework via Cookiebot. However, the lack of visible security headers such as Content-Security-Policy and absence of published security policies or incident response contacts represent areas for enhancement. No vulnerabilities or exposed sensitive data were detected in the content. The site does not provide a vulnerability disclosure program or security.txt file, which could improve transparency and trust. Overall, the security posture is adequate for an enterprise healthcare website but could benefit from additional best practices and disclosures.

Recommendations

  1. Implement and publish a comprehensive security policy including incident response contacts.
  2. Add security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options to enhance protection.
  3. Establish a vulnerability disclosure program and publish a security.txt file to facilitate responsible reporting.
  4. Consider providing direct contact information for security or privacy concerns to improve transparency.
  5. Regularly review and update cookie and privacy policies to maintain compliance with evolving regulations.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Biogen
Description
Biogen ist ein weltweit führendes Biotechnologie-Unternehmen und entwickelt innovative Arzneimitteltherapien für komplexe und schwere Erkrankungen. Die Forschungspipeline umfasst Wirkstoffkandidaten in Neurologie, Neuropsychiatrie, Immunologie und seltenen Erkrankungen.
Key services
Forschung und Entwicklung von Arzneimitteln, Produkte und Services für Patienten und medizinische Fachkreise, Information und Engagement im Gesundheitsbereich
Content quality
excellent
Branding
consistent

Technology

Stack
jQuery 3.6.4, Adobe Helix RUM, Cookiebot, Google Tag Manager, Google Analytics
Frameworks
Adobe Experience Manager (AEM)
Performance
moderate
Mobile
excellent
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • HttpOnly cookies
  • Cookie consent management

Analytics and tracking

Services
Google Analytics
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Cookiebot
Marketing tools
Cookiebot
Transparency
good

Site quality

Design
excellent
User experience
excellent
Content relevance
excellent
Navigation
excellent
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges
  2. Comprehensive cookie consent mechanism implemented via Cookiebot
  3. Strong focus on healthcare and biotechnology content
  4. Multiple language and regional site links available
  5. Social media presence on major platforms (YouTube, Instagram, LinkedIn, Facebook)
  6. No direct contact emails or phone numbers found in visible content
  7. Contact available via contact form page
  8. No explicit security policy or incident response information publicly disclosed
  9. No vulnerability disclosure or security.txt found
  10. Use of modern CMS (Adobe Experience Manager) and standard analytics tools
Technical notes

Notes

The website is built on Adobe Experience Manager, a robust enterprise CMS, and hosted on AWS infrastructure, ensuring scalability and reliability. The tech stack includes modern JavaScript libraries like jQuery 3.6.4 and integrates Google Analytics and Google Tag Manager for analytics and marketing. Cookiebot is used for consent management, reflecting GDPR compliance. The site is mobile-optimized with responsive design and good accessibility features. Performance is moderate, with potential for optimization in loading speed. The technical implementation is professional and aligns with industry standards for enterprise healthcare websites.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with biogen.de. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review biogen.de.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.